OSE has announced the presentation of its new proprietary ‘Cis-Demasking’ bispecific technology called OSE-CYTOMASK, for the design of novel cytokine drugs. OSE-CYTOMASK is a non-cleavable linker technology intended to generate regulated and targeted cytokine therapeutics for the delivery of highly active medicines with improved therapeutic indexes. Management will be presenting further details about OSE-CYTOMASK at a series of upcoming conferences, discussing its preclinical programmes based on an anti-PD1 masked cytokine (IL-2, IL-15), with conditional Cis-Demasking and Cis-Potentiation of tumour-specific T cells expressing PD1 or other immune targe targets.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment